中文摘要：

目的：观察肾康注射液治疗慢性肾脏疾病（CKD 3-4期）的临床疗效。方法：96例患者分为两组,试验组给予肾康注射液100 ml＋10%葡萄糖（或者0.9%氯化钠注射液）300 ml静脉滴注每日1次,对照组给予前列地尔注射液5μg＋生理盐水10 ml静脉注射每日1次,疗程为14 d,监测治疗前后患者的血肌酐（Scr）、尿素氮（BUN）、肌酐清除率（Ccr）、中医症候积分等指标变化情况。结果：与自身基线水平相比,治疗后两组患者Scr、BUN、Ccr、中医症候积分均有明显变化,比较差异有统计学意义（P〈0.05）,试验组总有效率为54.17%,对照组总有效率为56.25%,两组比较差异无统计学意义。结论：肾康注射液能有效延缓中医辨证分型为湿浊证和（或）血瘀证CKD3-4期患者病程的进展。

英文摘要：

Objective：To observe the efficacy of Alprostadil and Shenkang in the treatment of chronic kidney disease （CKD,stage 3-4）. Methods：96 cases of CKD（stage 3 -4） patients were divided into two group：shenkang group（48 patients） were given 100 ml Shenkang which was dissolved in 300 ml 10% glucose solution/0. 9% sodium chloride injection once a day; Al-prostadil group（48 patients） were treated with 5 μg Alprostadil Injection which was dissolved in 10 ml 0. 9% sodium chloride injec-tion once a day, its efficacy and safety would be evaluated after treatment for 14 days. Contrast the concentration of the serum creati-nine, blood urea nitrogen. Creatinine Clearance Rate and serum lipid, lipoprotein, the scores of traditional Chinese medical syn-drome, before and after the treatment. Results：After treatment, the clearance rate of Scr and Ccr of the patients were improved signif-icantly （P〈0. 05） in two group. The overall effective rate of shenkang group was 54. 17% and the overall effective rate of Alprostadil group achieved 56. 25%, but no differences were found between the two groups （P〉0. 05）. Conclusion：Shenkang Injection has an abvious therapeutic effect on CKD （stage 3-4） presented damp retardarced symptom and/or blood stasissed symptom.